Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Research

Contineum Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise, dedicated to the discovery and advancement of innovative oral small molecule therapies. Their primary focus lies in addressing neurological, inflammatory, and immunological disorders characterized by significant unmet medical needs. The company's foremost therapeutic candidate is PIPE-791, a pioneering, brain-penetrant small molecule designed to inhibit the lysophosphatidic acid 1 receptor (LPA1R). This compound is currently being investigated for its potential in treating idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). Additionally, Contineum is developing PIPE-307, a novel small molecule functioning as a selective inhibitor of the muscarinic type 1 M1 receptor, intended for the management of depression and relapse-remitting MS. Another asset in their pipeline is CTX-343, an LPA1R antagonist with activity restricted to the periphery. Founded in 2009, this San Diego, California-headquartered organization was formerly known as Pipeline Therapeutics, Inc. before officially changing its name to Contineum Therapeutics, Inc. in November 2023.

Open Contineum Therapeutics, Inc. Class A Common Stock (CTNM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.